Advertisement
Research ArticleArticle

Diltiazem Inhibition of Cytochrome P-450 3A Activity Is Due To Metabolite Intermediate Complex Formation

David R. Jones, J. Christopher Gorski, Mitchell A. Hamman, Bradley S. Mayhew, Steven Rider and Stephen D. Hall
Journal of Pharmacology and Experimental Therapeutics September 1999, 290 (3) 1116-1125;

Abstract

Diltiazem (DTZ) N-demethylation occurs by cytochrome P-450 (CYP) 3A based on the following observations: 1) a single enzyme Michaelis-Menten model of metabolite formation, 2) high correlations of DTZ N-demethylation activity to other CYP3A activities, 3) inhibition of DTZ N-demethylation activity by triacetyloleandomycin, and 4) DTZ N-demethylation activity by expressed CYP3A enzymes only. The meanKms for DTZ N-demethylation in human liver microsomes and expressed CYP3A4(+b5) were 53 and 16 μM, respectively. A 30-min preincubation of DTZ in expressed CYPs inhibited CYP3A4(+b5) by 100%, of which 55% was due to formation of a metabolite intermediate complex (MIC), which is an inactive form of CYP. MIC was observed in human liver microsomes and cDNA-expressed CYP3A only. In experiments to assess simultaneous MIC formation and loss of CYP3A activity, DTZ caused greater than 80% inhibition of midazolam hydroxylation after a 60-min preincubation in human liver microsomes. The rate constants for MIC formation and loss of midazolam hydroxylation activity were equivalent for the line of best fit for both data sets, which illustrates that MIC formation causes the inhibition of CYP3A activity. The mechanistic inhibition was characterized in expressed CYP3A4(+b5), which exhibited a concentration-dependent formation of MIC by DTZ (1–100 μM) with an estimated kinact of 0.17 min−1 and KI of 2.2 μM. The partition ratio for expressed CYP3A4(+b5) was substrate concentration dependent and varied from 13 to 86. This study showed that DTZ inhibition of CYP3A substrate metabolism occurs primarily by MIC formation.

Diltiazem (DTZ) is a benzothiazepine calcium channel blocker, which is widely used as a chronic therapy for the treatment of hypertension.N-demethylation of DTZ to N-desmethyldiltiazem (MA) is the primary pathway of elimination in humans, with lesser contributions from O-demethylation and deacetylation (Yeung et al., 1996). Recently, it was reported that MA formation is catalyzed primarily by cytochrome P-450 (CYP) 3A4 in human liver with minor contributions by CYP2C8 and CYP2C9 (Sutton et al., 1997). When DTZ is prescribed for long-term treatment a high potential of undesirable drug interactions occurs with other CYP3A substrates. Examples of compounds that are metabolized by CYP3A and whose elimination is inhibited by DTZ include cyclosporin A, nifedipine, quinidine, midazolam, alfentanil, triazolam, and lovastatin (Toyosaki et al., 1988; Leibbrandt and Day, 1992; Backman et al., 1994; Laganière et al., 1996; Ahonen et al., 1996; Varhe et al., 1996; Azie et al., 1998). The effect of DTZ is to reduce both the first-pass elimination and the systemic clearance of these coadministered drugs. This reduction of hepatic, systemic, CYP3A metabolism occurs in addition to the inhibition of CYP3A in the intestinal wall. Although DTZ is one of the most well established causes of clinically significant drug interactions with CYP3A enzymes, the mechanism of this inhibition is unclear.

Some recent reports have attempted to characterize the mechanism by which DTZ inhibits CYP3A. In vitro studies with rat liver microsomes and human hepatocytes suggested that DTZ inhibition of CYP3A was best described by competitive or noncompetitive inhibition, withKis ranging from 20 to 50 μM (Murray and Butler, 1996; Brockmöller et al., 1990). The steady-state plasma concentration of DTZ in humans during chronic DTZ treatment is approximately 0.3 μM (Yeung et al., 1996) and therefore, significant inhibition of CYP3A by DTZ via competitive or noncompetitive inhibition is not expected. A clinical study suggested that DTZ metabolites might cause the observed inhibition, because after 2 weeks of DTZ therapy, the elimination half-life of DTZ was significantly longer than that observed following a single dose and an unexpected accumulation of drug occurred (Montamat and Abernethy, 1987). Subsequently, Sutton et al. (1997) demonstrated that DTZ and its metabolites, MA andN,N-didesmethyldiltiazem, were competitive inhibitors of CYP3A in human liver microsomes, withKis approaching 2 μM for MA and 0.1 μM for N,N-didesmethyldiltiazem (Sutton et al., 1997). However, the reported steady-state plasma concentration of MA is 0.15 μM and the concentration of N,N-didesmethyldiltiazem has not been reported (Yeung et al., 1996). Again, because the plasma levels of the metabolites are much lower than the reportedKi, this would not explain the CYP3A inhibition by DTZ or its metabolites through a reversible mechanism. It remains possible that DTZ and/or a metabolite partition into the tissues that express CYP3A to reach inhibitory levels, but the alternative that inhibition is not simply competitive in nature must also be considered.

An additional inhibitory property exhibited by DTZ is the formation of a metabolite intermediate complex (MIC), a complex of metabolite and CYP, that is catalytically inactive (Bensoussan et al., 1995) and serves to reduce the pool of active CYP (Franklin, 1977). DTZ forms a MIC in vitro and in vivo in dexamethasone- and phenobarbital-induced rat liver microsomes (Bensoussan et al., 1995). To date there has been no demonstration that DTZ forms a MIC with human CYP3A enzymes, and the potential role of this phenomenon in mediating clinical drug interactions has not been evaluated. In this study we demonstrate that DTZ N-demethylation occurs primarily via CYP3A, show that DTZ forms a MIC with human CYP3A, and report that DTZ inhibition of CYP3A catalysis occurs primarily by MIC, not by reversible inhibition.

Materials and Methods

Chemicals.

α-Naphthoflavone (α-NF), caffeine, coumarin, desmethyldiazepam, dextromethorphan, diethyldithiocarbamic acid, diltiazem, 7-ethoxyresorufin, 7-ethoxytrifluoromethylcoumarin, 7-hydroxytrifluoromethylcoumarin, 4-methylpyrazole, paraxanthine, potassium ferricyanide, quinidine, resorufin, sodium hydrosulfite, and triacetyloleandomycin were purchased from Sigma Chemical Co. (St. Louis, MO). Chlorzoxazone, dextrorphan, furafylline, 6-hydroxychlorzoxazone, 7-hydroxycoumarin, 4-hydroxymephenytoin, 4-hydroxytolbutamide, and tolbutamide were purchased from Research Biochemicals International (Natick, MA). Sulfaphenazole and mephenytoin were gifts from CIBA-Geigy (Summit, NJ) and Sandoz (East Hanover, NJ), respectively. N-desmethyldiltiazem was a gift from Tanabe Seiyaku Co. (Osaka, Japan). Midazolam, 1′-hydroxymidazolam, and 4-hydroxymidazolam were a gift from Hoffmann-LaRoche (Nutley, NJ). All HPLC and microsomal preparation supplies were of the highest grade available from standard commercial sources. [β-NADP, isocitrate dehydrogenase (Type IV-purified), and isocitrate were purchased from Sigma Chemical Co. Disodium phosphate, magnesium chloride, and sodium phosphate were purchased from Fisher Scientific (Pittsburgh PA). NADPH (98%) was purchased from Boehringer Mannheim (Indianapolis, IN)].

Specimens.

Human adult liver specimens were obtained at surgery in accordance with protocols approved by the appropriate Committee for the Conduct of Human Research (The Medical College of Virginia, Richmond, VA; The Medical College of Wisconsin, Milwaukee, WI; The University of Michigan, Ann Arbor, MI; and Indiana University, Indianapolis, IN). The handling, preparation, and storage of microsomes along with characteristics of the microsomal samples and relative CYP3A levels have been previously described (Gorski et al., 1994a,b). CYP concentrations, if detectable, were quantified in each liver by the method of Omura and Sato (1964). The human liver microsomal samples along with their CYP concentrations are listed below: IUL-2, 0.25; IUL-3, 0.35; IUL-6, 0.31; IUL-10, 0.61; IUL-11, 0.44; and IUL-12, 0.1 nmol CYP/mg protein. The patient whose liver is designated IUL-10 was prescribed rifampin, a known inducer of CYP3A.

DTZ N-demethylation in Human Liver Microsomes.

Microsomes from four human livers were used to characterize DTZ N-demethylation. All microsomal incubations contained the components listed below: 50 μg microsomal protein, 100 mM sodium phosphate buffer (pH = 7.4) containing 5 mM magnesium chloride and up to 1.6 mM DTZ in a final volume of 500 or 1000 μl. The energy for the microsomal oxidation was supported by 1 mM NADPH or 5 mM isocitrate, 1U isocitrate dehydrogenase, and 1 mM β-NADP. The reaction mixture was started by adding β-NADP or NADPH, incubated at 37°C for 5 min, unless otherwise noted, and terminated by adding 1000 μl of acetonitrile. The samples were stored at −70°C until analysis.

Inhibitor Screen of DTZ N-demethylation.

The effects of putative inhibitors on MA formation were determined at a DTZ concentration of 0.5 mM in human liver microsomes (50 μg protein/sample). Each inhibitor was investigated with at least three concentrations. The inhibitor, the specific CYP it affects, and the range of concentrations of each are listed below: α-NF (1A2), 0.5 to 5 μM; furafylline (1A2), 5 to 100 μM; coumarin (2A6), 10 to 1000 μM; sulfaphenazole (2C9), 5 to 50 μM; S-mephenytoin (2C19), 5 to 100 μM; quinidine (2D6), 0.5 to 2.5 μM; 4-methylpyrazole (2E1), 25 to 100 μM; diethyldithiocarbamate (2E1), 50 to 1000 μM; triacetyloleandomycin (3A4/5), 20 to 500 μM. The inhibitor was assessed to have an effect if a consistent stimulation or inhibition greater than 10% was observed.

Correlations of Activity with DTZN-demethylation.

Twenty-one human liver microsomal preparations (50 μg protein/sample) were incubated with 1 mM DTZ for 15 min to assess the N-demethylation activity. Correlation analyses were performed on the N-demethylation activity and activity of previously characterized CYP pathways: CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP4A11 (Wrighton et al., 1993; Hall et al., 1994; Gorski et al., 1994a; Castle et al., 1995).

DTZ N-demethylation in cDNA-Expressed CYP.

Microsomes of B-lymphoblastoid cells expressing individual CYPs were employed to further assess the enzyme(s) involved in the biotransformation of DTZ to MA. These microsomes (200 μg/sample) were incubated with 0.5 mM DTZ for 15 min. Additionally, Michaelis-Menten kinetics of DTZ N-demethylation were performed with microsomes of CYP2A6 and with microsomes from baculovirus-infected insect cells (Supersomes CYP3A4, CYP3A4(+b5), and CYP3A5). In the latter experiments DTZ (5–500 μM) was incubated with 200 μg of microsomal protein or 40 pmol of CYP for 5 min. An incubation varying time was first performed to determine linear conditions.

Preincubation of DTZ with Expressed Enzymes.

DTZ (10 μM) was preincubated with individual cDNA-expressed CYPs (Supersomes or B-lymphoblastoid cells; Gentest Corp, Woburn MA), and NADPH for 30 min. Then an aliquot was removed and added to a tube containing the selective substrate for each CYP and NADPH. The selective substrate, concentration of substrate, CYP, and picomoles of CYP used for each treatment were: 1000 μM of caffeine, 50 pmols of CYP1A1 and CYP1A2, 5 μM of 7-ethoxyresorufin, 10 pmols of CYP1B1, 400 μM of coumarin, 27 pmols of CYP2A6, 10 μM of 7-ethoxytrifluoromethylcoumarin, 50 pmols of CYP2B6, 200 μM of tolbutamide, 50 pmols of CYP2C8 and CYP2C9-Arg144, 100 μM ofS-mephenytoin, 50 pmols of CYP2C19, 50 μM of midazolam, 20 pmols of CYP3A4(+b5), CYP3A4, and CYP3A5, 500 μM of lauric acid, and 50 pmols of CYP4A11. The dilution of the aliquot from the preincubation tube with the contents of the tube containing the selective substrate was 1:10 (v/v) to eliminate competitive inhibition as a possible cause of the inhibitory effect. After a 5- to 15-min incubation, the reaction was terminated and then assayed for activity. A control that contained the selective substrate, cDNA-expressed CYP, and NADPH was incubated for 5 to 15 min. The reaction was terminated and then assayed for activity. The percentage of inhibition was estimated with the following equation: ((control activity-treatment activity)/control activity)*100. When the percentage of inhibition by the DTZ (+NADPH) preincubation tube was greater than 30%, additional incubations were performed to resolve the reversible inhibition component underlying the inhibitory effect of DTZ. Thus, DTZ was preincubated with individual cDNA-expressed CYPs in the absence of NADPH for 30 min. Then an aliquot was removed and added to a tube containing the selective substrate for each CYP and NADPH. After a 5- to 15-min incubation, the reaction was terminated and then assayed for activity. The percentage of inhibition of the DTZ (−NADPH) in the preincubation tube was compared with the control that was not preincubated to assess the reversible inhibition.

Metabolite Intermediate Complex Formation.

Microsomes from six human livers were used to characterize MIC formation by DTZ. In two of the human liver microsomal preparations DTZ concentrations were varied from 0.1 to 100 μM to determine whether substrate was a limiting factor involved in MIC formation. MIC formation was identified with dual wavelength spectroscopy (Uvikon 933 double beam UV/VIS Spectrophotometer; Research Instruments International, San Diego, CA) by scanning from 380 to 500 nm and was quantified by wavelength programming of four wavelengths, selected from the original scans, at 30-s intervals. In each case, the sample cuvette contained protein (usually 500 μg), substrate, and NADPH, whereas the reference cuvette contained protein, substrate vehicle, and NADPH. All MIC formation experiments were initiated by the addition of NADPH and maintained at 37°C. The absorbance difference spectra for the identification of MIC formation were estimated by subtracting the absorbance at 490 nm of the absorbance scan from the difference of the absorbance scan at a given time and a background absorbance scan. The results from the wavelength program runs were estimated by subtracting the absorbance at 490 nm from the absorbance of a given wavelength, usually 452 nm, at a specific time.

Supersomes [CYP2B6, CYP3A4, CYP3A4(+b5), and CYP3A5] were used to characterize MIC formation by DTZ. MIC formation was assessed in CYP2B6 because the substrate selectivities of it and CYP3A are similar (Ekins et al., 1999). The CYP concentration was 800 pmol/cuvette for CYP3A4 and CYP3A5 and 200 pmol/cuvette for CYP2B6 and CYP3A4(+b5). The procedure to measure MIC formation was the same as that described above for human liver microsomes.

K3Fe(CN)6, a compound that dissociates MIC, was used to dissociate “in vivo”-formed MIC by DTZ. Initially, DTZ (10 μM) was incubated with human liver microsomes and NADPH to allow MIC formation. After 90 min the sample cuvette was split such that half of the contents were placed in a reference cuvette and the other half were used as the sample cuvette. K3Fe(CN)6 (10 μl of 5 mM) was added to the reference cuvette and vehicle (10 μl of water) was added to the sample cuvette using the procedure described by Wrighton et al. (1985). The cuvettes were scanned from 380 to 500 nm at 5, 10, and 15 min (Roos et al., 1993), and the absorbance difference spectra were estimated as noted above.

Preincubation of DTZ with Human Liver Microsomes.

DTZ (100 μM) or alprazolam (400 μM) were incubated in human liver microsomes with NADPH to simultaneously quantify MIC formation and midazolam hydroxylation inhibition. Alprazolam was selected as the control compound because it is metabolized by CYP3A but does not form a MIC based on preliminary experiments and to assess whether all CYP3A substrates cause an irreversible inhibition. The DTZ concentration was chosen to maximize DTZ in the preincubation. In conjunction with the MIC formation, DTZ or alprazolam were preincubated in human liver microsomes with NADPH at various times (0.5–60 min), whereupon a sample was removed and added to a tube containing midazolam (100 μM) and NADPH. The dilution of the aliquot from the preincubation tube with the contents of the tube containing midazolam was 1:10 (v/v) to eliminate competitive inhibition as a possible cause of the inhibitory effect. After a 5-min incubation, the midazolam metabolism was terminated by the addition of acetonitrile, then the tube was partially submerged into an acetone/dry ice bath for about 10 min to freeze the aqueous matrix. 1′-Hydroxy- and 4-hydroxymidazolam were quantified by gas chromatograph-mass spectrometry as reported previously (Gorski et al., 1998). Gas chromatograph-mass spectrometry was employed in this assay because the HPLC procedure cannot resolve midazolam metabolites from alprazolam metabolites.

Quantification of Enzyme Activity.

MA was quantified by HPLC with UV detection (237 nm). The metabolic pathway, UV setting, and selective CYP activity are listed for each CYP sample that was quantified by HPLC: caffeine 3-N-demethylation (270 nm), CYP1A1 and CYP1A2 (Miners and Birkett, 1996a); tolbutamide 4-hydroxylation (235 nm), CYP2C8 and CYP2C9 (Miners and Birkett, 1996b); mephenytoin 4-hydroxylation (235 nm), CYP2C19 (Wedlund and Wilkinson, 1996); midazolam 1′-hydroxylation and 4-hydroxylation (230 nm), CYP3A4 and CYP3A5 (Gorski et al., 1994b). 7-Ethoxyresorufin O-deethylation, coumarin 7-hydroxylation, and 7-ethxoytrifluoromethylcoumarin O-deethylation were quantified by fluorescence to assess selective CYP1B1, CYP2A6, and CYP2B6 activities, respectively (Miles et al., 1990; Buters et al., 1993; Crespi et al., 1997). Dextromethorphan O-demethylation was quantified by HPLC with fluorescence detection (excitation 190 nm, emission 310 nm) to assess CYP2D6 activity (Jones et al., 1996). Lauric acid 12-hydroxylation was quantified by fluorescence derivatization, HPLC, and fluorescence detection (excitation 340 nm, emission 420 nm) to assess CYP4A11 activity (Powell et al., 1996). All substrates and inhibitors were tested for interference before use and no interferences were detected.

Metabolite Intermediate Complex Data Analysis.

MIC was quantified from absorbance difference spectra using an extinction coefficient of 65 mM−1 (Pershing and Franklin, 1982). The pseudo first-order rate constant for enzyme inactivation, λ, was estimated from the initial rate of enzyme inactivation (0–5 min) with eq. 1.E(t)=E0·e−λ·t Equation 1where E(t) is the percentage of active enzyme remaining at time (t) andE0 is 100%. The relationship between λ and inhibitor concentration was fitted to the following equation:λ=kinact·[I]/(KI+[I]) Equation 2where kinact is the rate constant for inactivation, [I] is inhibitor, or inactivator concentration, and KI is the inactivator concentration that produces half the maximal rate of inactivation, analogous to a Km(Silverman, 1988). Equation 2 assumes there is negligible change of [I] in the incubation period and that loss of enzyme is due to inactivation. The partition ratio, r, is the number of moles of metabolite formed per mole of enzyme inactivated and is determined from the ratio ofkcat/kinact, where kcat was determined from the ratio of Vmax of MA formation to moles of CYP3A (Waley, 1985).

Data Analysis and Statistics.

The microsomal activity data represent the mean of duplicate or triplicate assays for every experiment. Untransformed kinetic data were analyzed by nonlinear regression without weighting (WinNonlin v 1.1; SCI Software, Apex, NC). The appropriateness of the fit was determined by the visual inspection of fit and residual patterns, residual sums of squares, and precision of the parameter estimates (Boxenbaum et al., 1974). The correlation coefficient and its corresponding statistical significance were determined by conventional methods (Rohlf and Sokal, 1981).

Results

Characterization of Diltiazem N-demethylation Activity.

After identifying linear conditions with respect to time and protein concentration, one enzyme or a family of enzymes with similar Kms appears to be involved in the formation of MA based on Michaelis-Menten plots from four human liver microsomal samples (Fig. 1). The mean (±S.D.) Km of four livers was 53 (±22.1 μM) and the Vmax ranged from 1,035 to 23,965 pmol/(mg protein · min). The resulting intrinsic clearances (Clint;Vmax/Km) ranged from 1 to 35 μl/min.

Figure 1
Figure 1

Diltiazem N-demethylation in human liver microsomes. Human liver microsomes (50 μg protein/sample) were incubated with diltiazem and NADPH for 5 min. Each symbol represents the average of two points. Each line represents the line of best fit with a single-enzyme Michaelis-Menten equation. ●, IUL-10; ○, IUL-12; ▪, IUL-3; ■, IUL-2.

The maximum rate of MA formation determined at 1000 μM DTZ was correlated with selective CYP activities in 14 to 21 adult liver microsomal samples described previously. These samples were characterized previously for relative amounts of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP4A11 and their form specific activities (Wrighton et al., 1993; Hall et al., 1994;Gorski et al., 1994a; Castle et al., 1995). The formation of MA correlated significantly with CYP3A activity, which included erythromycin N-demethylase activity (r = 0.88, n = 14, p < .01), midazolam 1′-hydroxylase activity (r = 0.96, n = 21, p < .01), midazolam 4-hydroxylase activity (r = 0.97, n = 21, p < .01), dextromethorphan N-demethylase activity (r = 0.95, n = 21, p < .01), and total CYP3A protein (r = 0.94,n = 14, p < .01). There was no significant correlation between the rate of MA formation and previously reported rates of ethoxyresorufin O-deethylation, coumarin 7-hydroxylation, taxol 6α-hydroxylation, phenytoin 4-hydroxylation,S-mephenytoin 4′-hydroxylation, bufuralol 1′-hydroxylation, chlorzoxazone 6-hydroxylation, N-nitrosodimethylamineN-demethylation, and lauric acid 12-hydroxylation, which primarily reflect the activities of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP2E1, and CYP4A11, respectively (Wrighton et al., 1993; Hall et al., 1994; Castle et al., 1995).

Selective inhibitors were used to further characterize the enzyme(s) responsible for the N-demethylation of DTZ in human liver microsomes. Triacetyloleandomycin was the only compound that strongly inhibited MA formation (Fig. 2). High concentrations of 4-methylpyrazole (75–100 μM) and diethyldithiocarbamate (1000 μM) also inhibited MA formation, but these inhibitor concentrations may have resulted in nonselective inhibition, which has been observed previously (Newton et al., 1995). Stimulation of MA formation was observed with α-NF and quinidine, which also has been reported previously for CYP3A- mediated catalysis (Newton et al., 1995; J.C.G., D.R.J., M.A.H., S.D.H., S. A. Wrighton, unpublished observations).

Figure 2
Figure 2

The effect of selective inhibitors onN-desmethyldiltiazem formation. Human liver microsomes (50 μg/sample; IUL-10) were incubated with inhibitor and 0.5 mM diltiazem. The reaction was initiated with NADPH. α-NF; 4-methylpyrazole; diethyldithiocarbamate (DDC); or triacetyloleandomycin (TAO). Each column represents the mean of two or three points with a single liver.

Microsomes of human B-lymphoblastoid cells that express human CYPs were used to confirm that CYP3A enzymes primarily catalyze the biotransformation of DTZ to N-desmethyldiltiazem. CYP3A4 exhibited the greatest DTZ N-demethylation activity in these expressed CYPs. The expressed CYP with the DTZ N-demethylase activity relative to CYP3A4 activity in percentages was CYP1A1, 0%; CYP1A2, 0%; CYP2A6, 23%; CYP2B6, 3%; CYP2C9, 1%; CYP2D6, 9%; CYP2E1, 5%; CYP3A4, 100%. Significant activity was associated with CYP2A6 and CYP2D6, but in view of the low relative abundance of these enzymes in vivo, they are unlikely to make a significant contribution to DTZ metabolism.

Enzyme kinetic parameters were estimated in CYP2A6 and CYP3A4 to further investigate the involvement of these expressed systems in DTZN-demethylation. No detectable formation of MA was observed with CYP2A6. However, MA formation was observed in expressed CYP3A4, CYP3A4(+b5), and CYP3A5 (Fig.3). The estimatedVmax in CYP3A4(+b5) (585 pmol/min) was greater than the Vmax for CYP3A4 and CYP3A5 (121 and 429 pmol/min, respectively) but less than theVmax for any of the human liver microsomal samples. The estimated Kms of CYP3A4(+b5) and CYP3A4 were nearly equal, 16 and 17 μM, respectively, and considerably less than theKm of CYP3A5 (81 μM). The calculated Clint values were 37, 7, and 5 μl/min for CYP3A4(+b5), CYP3A4, and CYP3A5, respectively.

Figure 3
Figure 3

Diltiazem N-demethylation in microsomes of cDNA-expressed CYP3A. Diltiazem (5–500 μM) was incubated with 40 pmol of cDNA-expressed CYP3A and NADPH for 5 min. Each symbol represents the average of two points. Each line represents the line of best fit with a single-enzyme Michaelis-Menten equation. ○, CYP3A4(+b5); ▪, CYP3A5; ■, CYP3A4.

Preincubation of DTZ with Expressed Proteins.

To assess the effect of DTZ on selective CYP activity, preincubation experiments (30 min) were performed with cDNA-expressed CYPs (Supersomes Gentest Corp., Woburn MA) and one CYP expressed from B-lymphoblastoid cells. The 30 min preincubation of DTZ with NADPH inhibited the control activity in CYP1B1 by 56%, CYP2A6 by 52%, CYP3A4(+b5) by 100%, CYP3A4 by 40%, and CYP3A5 by 59%. Next, the aforementioned CYPs were preincubated with DTZ in the absence of NADPH to determine the reversible inhibitory contribution of DTZ. Only CYP3A4(+b5) exhibited a significant mechanistic inhibitory component, which resulted in 55% of the total inhibition. In comparison, CYP1B1, CYP2A6, CYP3A4, and CYP3A5 exhibited less than 5% of the total inhibition as a mechanistic component. The time-dependent inhibition with CYP3A4(+b5) may be due to the formation of a MIC with CYP, which would inactivate the enzyme.

MIC Formation by Diltiazem.

Triacetyloleandomycin was used initially as the prototypical compound to substantiate measurement of MIC formation in human liver microsomes. After incubation of triacetyloleandomycin with human liver microsomes and NADPH, a dependent increase in absorbance at 455 nm was observed that is characteristic of the formation of a MIC (data not shown; Wrighton et al., 1985).

Upon incubation of DTZ with human liver microsomes and NADPH, a peak absorbance difference was observed at 452 nm (Fig.4A) but not in the absence of NADPH. Additional NADPH, which was supplemented to the sample at 20-min intervals during data collection, and O2 gassing, which was supplemented to the sample for 5 s at 10-min intervals, had no effect on MIC formation by DTZ (data not shown; Franklin, 1991). After DTZ was incubated with human liver microsomes and NADPH for 90 min (Fig. 4A), the sample containing MIC was split into two cuvettes, one was used as the reference cuvette and the other as the sample cuvette. Then, K3Fe(CN)6was added to the reference cuvette. At 15 min, a peak absorbance difference was detected at 452 nm in the sample cuvette only, indicating a degradation of complex in the reference cuvette (Fig. 4B). The dissociation at 15 min by K3Fe(CN)6 was greater than 93%, which substantiates that DTZ forms a MIC in human liver microsomes.

Figure 4
Figure 4

A, metabolite intermediate complex formation by diltiazem (10 μM) in human liver microsomes. Sample cuvette contained human liver microsomes, diltiazem, and NADPH, whereas reference cuvette contained human liver microsomes, buffer, and NADPH. Absorbance was monitored from 0 to 90 min. Lines represent change in absorbance difference for scans at 15, 30, 45, 60, 75, and 90 min. B, K3Fe(CN)6 dissociation of “in vivo” formed metabolite intermediate complex by diltiazem. After a 90-min incubation of diltiazem (10 μM), human liver microsomes, and NADPH to form metabolite intermediate complex (A), the sample cuvette was split. Half the contents were placed in the reference cuvette and the other half was used as the sample cuvette. Then K3Fe(CN)6was added to the reference cuvette and vehicle was added to the sample cuvette. Absorbance was monitored at 0, 5, 10, and 15 min. Lines represent change in absorbance difference for scans at 5, 10, and 15 min.

The ability of DTZ to form a MIC was assessed in microsomes of five human livers that contained varying amounts of CYP3A. The magnitude of the MIC increased with time and exhibited a maximum absorbance difference of 0.015 at 452 nm in microsomes of one human liver (Fig.4A). MIC formation by DTZ (10 μM) measured by continuous monitoring (452–490 nm) from 0 to 80 mins in the same human liver microsomes, although at a decreased total protein concentration, is illustrated in Fig. 5. The estimated λ from eq. 1 and maximum MIC (MICmax) were 0.025 and 0.0068 min−1, respectively. The MICmax is 87% of the total CYP in the sample applying the extinction coefficient of 65 mM−1(Pershing and Franklin, 1982). The MICmax of DTZ was quantified in five of the human liver microsomal samples. Figure6 illustrates the correlation of maximum DTZ N-demethylation activity (Fig. 6A) or maximum midazolam hydroxylation activity (Fig. 6B) with MICmax (in picomoles) in these microsomal samples (r ≥ 0.99). These data show that MIC formation by DTZ correlates with CYP3A.

Figure 5
Figure 5

Metabolite intermediate complex formation by diltiazem (10 μM) in human liver microsomes. The points represent continuous scanning measurement of absorbance difference (455–490 nm) over time. The line represents the line of best fit.

Figure 6
Figure 6

Correlation of maximum metabolite intermediate complex formation with maximum CYP3A activity in human liver microsomes. A, correlation of maximum diltiazemN-demethylation activity with maximum metabolite intermediate complex formation in five human liver microsomal samples. B, correlation of maximum midazolam hydroxylation activity with maximum metabolite intermediate complex formation in five human liver microsomal samples. Experimental conditions for MIC measurements were the same as Fig. 4. Diltiazem (1 mM) was incubated with human liver microsomes and NADPH for 15 min to quantify maximum diltiazemN-demethylation activity. Midazolam (400 μM) was incubated with human liver microsomes and NADPH for 5 min to quantify maximum midazolam 1′-hydroxylase activity. Each symbol represents the mean of two points.

Dual wavelength scanning experiments to quantify MIC formation by DTZ were performed with cDNA-expressed CYP2B6, CYP3A4(+b5), CYP3A4, and CYP3A5 because CYP3A exhibited a mechanistic inhibition component upon preincubation with DTZ (vide supra), and because CYP2B6 shares substrate selectivities with CYP3A. CYP3A4(+b5) allowed extensive MIC formation (Fig. 7). The magnitude of the MIC increased with time and exhibited a MICmax of 0.0061 at 450 nm. The estimated MICmax was 61% of the total CYP in the sample. The formation of MIC was evident in expressed CYP3A4 and CYP3A5, reaching approximately 10% of the total CYP in 90 mins (Fig. 7). No MIC formation was supported by CYP2B6.

Figure 7
Figure 7

Metabolite intermediate complex formation by diltiazem in microsomes of cDNA expressed CYP3A. Experimental conditions for MIC measurements were the same as Fig. 4. The CYP concentration was 800 pmol/cuvette for CYP3A4 and CYP3A5 and 200 pmol for CYP3A4(+b5). Each symbol represents the average of two points. Each line represents the line of best fit to the data. ●, CYP3A4(+b5); ▪, CYP3A5; ■, CYP3A4.

The effect of DTZ concentration (0.1–100 μM) on MIC formation was studied in human liver microsomes and expressed CYP3A4(+b5). MIC formation by DTZ was quantified by continuous wavelength monitoring and the resulting enzyme inactivation data were fit to eq. 1. There was no evidence of concentration-dependent MIC formation in the human liver microsomal samples. The cDNA expressed CYP3A4(+b5) illustrated a concentration-dependent formation of MIC by DTZ (1–100 μM) with an estimated kinact of 0.17 min−1 and KI of 2.2 μM (Fig. 8). The partition ratio,kcat/kinactfor expressed CYP3A4(+b5) was 86.

Figure 8
Figure 8

Rate of metabolite intermediate complex formation by diltiazem in cDNA-expressed CYP3A4(+b5). CYP3A4(+b5) was incubated with diltiazem (1–100 μM) and NADPH, and then MIC was monitored. The estimates of λ from initial rates of enzyme degradation (eq. 1) were plotted against diltiazem concentration. The line represents the line of best fit with eq. 2. kinact = 0.17 min−1; KI = 2.2 μM.

Preincubation of DTZ with Human Liver Microsomes.

To further understand the role of DTZ MIC formation on CYP3A activity, simultaneous preincubation and MIC formation experiments were performed with human liver microsomes. DTZ or alprazolam were preincubated for various times with microsomes containing NADPH, then added to a matrix that contained midazolam and NADPH. Alprazolam, which was used as a control compound because it has not shown any MIC formation and is a CYP3A substrate, caused a 30% loss in midazolam hydroxylation activity after a 60-min preincubation. The simultaneous MIC formation by DTZ and the effect of DTZ preincubation on midazolam hydroxylation in human liver microsomes are illustrated in Fig.9. DTZ caused greater than 80% inhibition of midazolam hydroxylation after a 60-min preincubation, again indicating that this does not reflect competitive inhibition because of the dilution that occurs before measuring residual catalytic activity. The rate constants (λ) for MIC formation and loss of midazolam hydroxylation activity were the same for the line of best fit for both sets of data, which illustrates that MIC formation causes the inhibition of midazolam hydroxylation.

Figure 9
Figure 9

The simultaneous measurement of metabolite intermediate complex formation by diltiazem and the effect of diltiazem preincubation on midazolam hydroxylation in human liver microsomes. A, metabolite intermediate complex formation by diltiazem. B, effect of diltiazem preincubation on midazolam hydroxylation in human liver microsomes. DTZ (100 μM) was incubated with human liver microsomes and NADPH for various times, and then added to a tube containing midazolam and NADPH. The midazolam reaction was terminated after a 5-min incubation. Each line is the line of best fit for the data. λ = 0.037 min−1; ▾, 1′-hydoxymidazolam; ▵, 4-hydroxymidazolam.

Discussion

It appears that one family of enzymes, CYP3A, is involved in DTZN-demethylation based on our observations of 1) a single- enzyme Michaelis-Menten model of metabolite formation (Fig. 1), 2) correlations of DTZ N-demethylation activity to other CYP3A activities (e.g., erythromycin N-demethylation, midazolam 1′-hydroxylation, midazolam 4-hydroxylation, and dextromethorphanN-demethylation), 3) inhibition of DTZN-demethylation activity by a selective CYP3A inhibitor only (e.g., triacetyloleandomycin; Fig. 2), and 4) DTZN-demethylation activity by expressed CYP3A4 and CYP3A5 only. These results are similar to those recently reported by Sutton et al. (1997), with the exception that a correlation between DTZN-demethylation activity and activity of substrates selective for CYP2C8 and CYP2C9 was observed and that DTZN-demethylation activity by expressed CYP2C8 and CYP2C9 also was observed. Our results did not indicate that CYP2C8 or CYP2C9 make a significant contribution to DTZ N-demethylation. In the initial cDNA-expressed CYP screen, CYP2A6 was implicated as an enzyme that may be involved in the formation ofN-desmethyldiltiazem. However, upon further investigation, no detectable N-desmethyldiltiazem was observed by CYP2A6 when DTZ substrate concentrations were increased from 5 to 500 μM. Therefore, our results indicate that DTZ N-demethylation is mediated by CYP3A enzymes only.

A major finding in this report is that DTZ forms a MIC with CYP3A in human liver microsomes. MICs are an inactive form of CYP that serve an inhibitory role in drug metabolism because they remove active CYP from the total CYP pool (Franklin, 1977). DTZ has been reported to form MICs in vitro and in vivo in dexamethasone- and phenobarbital-induced rat liver microsomes (Bensoussan et al., 1995), but before this study no one had reported MIC formation by DTZ in human liver microsomes or human CYP3A enzymes. Triacetyloleandomycin, a macrolide antibiotic, was used initially as the prototypical compound to substantiate measurement of MIC formation in human liver microsomes (Pershing and Franklin, 1982). After incubation of triacetyloleandomycin with human liver microsomes and NADPH, an absorbance difference was observed at 455 nm, which is characteristic of many MICs (Bensoussan et al., 1995). When DTZ was incubated with human liver microsomes and NADPH, a MIC was detected but not in the absence of NADPH. However, MIC formation by DTZ is small in comparison with metabolism. There is substantial metabolism of DTZ to MA and it is assumed that a metabolic product of MA causes the MIC formation (Bensoussan et al., 1995). Our laboratory interprets the small MIC formation by DTZ to be a result of competitive inhibition of MA metabolism by DTZ. This in turn would inhibit MIC formation.

The importance of CYP3A4 in MIC formation by DTZ was shown in several experiments. First, the correlation of maximum DTZN-demethylation or midazolam hydroxylation (markers of CYP3A activity) with MICmax by DTZ in human liver microsomal samples was 0.99 (Fig. 6). Second, the preincubation of DTZ with expressed CYP showed a 55% inhibition of CYP3A4(+b5) catalytic activity toward midazolam 1′-hydroxy formation that was a result of some type of inhibition other than reversible inhibition. Third, expressed CYP3A4(+b5) formed MIC in a time-dependent fashion that inactivated greater than 60% of the CYP (Fig. 7). These data illustrate that DTZ forms a MIC in human liver microsomes, that this MIC formation is due to CYP3A4, that MIC formation by DTZ can be reproduced in expressed CYP3A4 (+b5), and that a majority of the CYP is inactivated by MIC from DTZ. Even though CYP3A4(+b5) allowed MIC formation, it was not complete (Fig. 7). One possible explanation for this was illustrated by Chiba et al. (1995). They showed that a 30-min preincubation of human liver microsomes with NADPH caused approximately 40% inhibition of activity associated with CYP3A. These data suggest that a preincubation with NADPH will cause enzyme degradation but the mechanism is unknown.

The result of MIC formation, inactive CYP, by DTZ may lead to a misinterpretation of drug interaction data. For example, it has been assumed that substrates metabolized by the same enzyme, when coadministered, will cause a reversible type of inhibition, usually competitive. In an in vitro study to understand DTZ inhibition, Sutton et al. (1997) suggested that DTZ, MA, andN,N-didesmethyldiltiazem inhibited CYP3A4 in a competitive manner, that metabolites exhibited much lowerKis than the parent compound, and that none of the compounds formed MICs. Steady-state plasma DTZ concentrations are 0.2 to 0.5 μM depending on the dosage (Höglund and Nilsson, 1989a; Yeung et al., 1996) and maximal plasma concentrations after single-dosage DTZ may reach as high as 0.6 μM (Höglund and Nilsson, 1989b). Steady-state plasma concentrations of MA are 0.15 μM andN,N-didesmethyldiltiazem concentrations have not been reported (Yeung et al., 1996). Because these concentrations are 100-fold less than the Ki (∼50 μM) for reversible inhibition, these results suggest that some type of inhibition is ongoing other than competitive inhibition. Thus, the in vitro data with Kis estimated from reversible inhibition models do not provide a good prediction of in vivo studies. To further understand the mechanism of DTZ inhibition of CYP3A, DTZ was preincubated with NADPH and human liver microsomes, then placed in a tube that contained a CYP3A marker, midazolam. MIC formation by DTZ was monitored over time along with the inhibition of midazolam hydroxylation. The inhibition of midazolam hydroxylation paralleled DTZ MIC formation (Fig. 9) and the line of best fit for each phenomenon had the same rate constant (λ = 0.037 min−1), which provided further evidence that DTZ inhibition of CYP3A4 occurred by MIC formation. These data also showed that MIC formation by DTZ will inhibit CYP3A activity in an irreversible manner and may be accountable for 100% of the inhibition.

The partition ratio,kcat/kinact, was 86 for DTZ in expressed CYP3A4(+b5), which illustrates, at least for the expressed CYP3A, that catalysis is a much more prevalent event than inactivation. However, theKI andKm values for DTZ were 2.2 and 16 μM, respectively, indicating that the partition ratio is dependent on DTZ concentration. For example, at a DTZ concentration of 0.3 μM, which is the steady-state plasma concentration, the partition ratio (= (kcat · substrate/(Km+ substrate))/(kinact · inactivator/(KI+ inactivator))) is 13. This value approximates the partition ratio for other potent inactivators of CYP3A in vitro (e.g., gestodene,r = 9; ritonavir, 10; and delavirdine, 41; Guengerich, 1990; Koudriakova et al., 1998; Voorman et al., 1998). These results suggest that DTZ may cause significant inhibition due to inactivation of CYP3A when administered clinically. A substrate concentration dependence in partition ratio was also noted for delavirdine. At low concentrations of delavirdine (≪KIor Km), the partition ratio is 130 assuming a KI of 21.6 μM and aKm of 6.8 μM, whereas, at high concentrations the partition ratio is 41 (Voorman et al., 1998). All these data illustrate that Km andKI should not be assumed to be equal, and therefore, inactivator concentration affects the partition ratio, which is important for making judgements about relative inactivation potential by CYP3A inhibitors.

Multiple studies have shown that DTZ inhibits the metabolism of compounds that are primarily metabolized by CYP3A, specifically, nifedipine, cyclosporin A, triazolam, quinidine, midazolam, alfentanil and lovastatin (Toyosaki et al., 1988; Brockmöller et al., 1990;Varhe et al., 1996; Laganière et al., 1996; Ahonen et al., 1996;Azie et al., 1998). Most of these studies attributed competitive inhibition as the mechanism of interaction, but the results of our findings suggest that the inhibition may be a result of MIC formation with DTZ. Consistent with this finding, chronic administration of DTZ provides evidence that DTZ affects its own disposition. DTZ exhibited a significantly prolonged half-life after multiple days of dosage and accumulated more than predicted from a single dose (Montamat and Abernethy, 1987). Increasing the dosage of DTZ resulted in an increase in bioavailability (Bianchetti et al., 1991). The area under the plasma concentration time curve (AUC) of DTZ in a dosing interval at steady state increased significantly compared with a single-dose AUC, indicating an increased bioavailability (Höglund and Nilsson, 1989c). Our data suggest that MIC formation by DTZ inhibits the metabolism of parent compound, but more studies are warranted to address this question.

Is MIC formation by DTZ a systemic occurrence or does it also occur in the intestinal wall that also expresses CYP3A4? Data from clinical studies suggest that DTZ inhibition of CYP3A occurs both in the intestinal wall and the liver. DTZ, initially administered orally followed by i.v. administration, caused a 25% increase in i.v. midazolam AUC and a 40% increase in i.v. alfentanil AUC. The interaction involved primarily hepatic metabolism because midazolam and alfentanil were administered i.v. (Ahonen et al., 1996). Conversely, the inhibition of oral lovastatin metabolism by oral DTZ is probably due to inhibition of intestinal wall and hepatic CYP3A. Oral DTZ increased lovastatin oral AUC without a simultaneous change in half-life, which suggests that DTZ inhibition of lovastatin occurs presystemically (Azie et al., 1998). These studies suggest that DTZ inhibition of CYP3A4 occurs at the intestinal wall and hepatic level and may be due to MIC formation.

Six human livers were used to study the correlation of maximum DTZ N-demethylation rate with maximum MIC formation. However, one of the livers contained CYP3A5 and was excluded in the correlation (Fig. 6). The DTZ N-demethylation in the liver containing CYP3A5 was greater than the maximum MIC formation when compared with the other five livers. This suggests that the partition ratio for CYP3A5 is higher than CYP3A4. In fact, the estimated partition ratio of CYP3A5, without b5, was 324 in comparison with 70 for CYP3A4, withoutb5. If CYP3A5 forms more MA than CYP3A4, then these results would agree with data previously published by our laboratory that showed that CYP3A5 favors the formation of 1′-hydroxymidazolam over 4-hydroxymidazolam (Gorski et al., 1994b). Thus, MA formation at high DTZ concentrations (>500 μM) could be used as a marker of significant CYP3A5 expression. Additionally, a liver expressing a high amount of CYP3A5 could be interpreted as a “protective” component because the enzyme forms less MIC with DTZ, which may result in less harmful drug interactions.

This study illustrated that DTZ metabolism toN-desmethyldiltiazem occurs by CYP3A and that DTZ inhibition of CYP3A substrate metabolism occurs primarily by MIC formation, which renders the CYP inactive.

Footnotes

  • Send reprint requests to: David R. Jones, Ph.D., Indiana University School of Medicine, Division of Clinical Pharmacology, Wishard Memorial Hospital, OPW 320, 1001 W. 10th St., Indianapolis, IN 46202. E-mail: drjones1{at}iupui.edu

  • ↵1 This work was supported in part by a grant (AG 13718) from the National Institutes of Health (Bethesda, MD).

  • Abbreviations:
    DTZ
    diltiazem
    α-NF
    α-naphthoflavone
    AUC
    area under the plasma concentration time curve
    Clint
    intrinsic clearance
    CYP
    cytochrome P-450
    kcat
    rate constant for catalysis
    kinact
    rate constant for inactivation
    Ki
    dissociation constant for reversible inhibition
    KI
    inactivator concentration that produces half the maximal rate of inactivation
    λ
    pseudo first-order rate constant
    MA
    N-desmethyl diltiazem
    MIC
    metabolite intermediate complex
    MICmax
    maximum metabolite intermediate complex
    r
    partition ratio
    Vmax
    maximum velocity of metabolite formation
    • Received December 7, 1998.
    • Accepted May 21, 1999.

References

  1. ↵
    1. Ahonen J,
    2. Olkkola KT,
    3. Salmenperä M,
    4. Hynynen M,
    5. Neuvonen PJ
    (1996) Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 85:1246–1252.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Azie NE,
    2. Brater DC,
    3. Becker PA,
    4. Jones DR,
    5. Hall SD
    (1998) The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 64:369–377.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Backman JT,
    2. Olkkola KT,
    3. Aranko K,
    4. Himberg J-J,
    5. Neuvonen PJ
    (1994) Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 37:221–225.
    OpenUrlPubMed
  4. ↵
    1. Bensoussan C,
    2. Delaforge M,
    3. Mansuy D
    (1995) Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem Pharmacol 49:591–602.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Bianchetti G,
    2. Regazzi M,
    3. Rondanelli R,
    4. Ascalone V,
    5. Morselli PL
    (1991) Bioavailability of diltiazem as a function of the administered dose. Biopharmaceut Drug Disp 12:391–401.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Boxenbaum HG,
    2. Riegelman S,
    3. Elashoff RM
    (1974) Statistical estimations in pharmacokinetics. J Pharmacokin Biopharm 2:123–148.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Brockmöller J,
    2. Heumayer HH,
    3. Wagner K,
    4. Weber K,
    5. Heinemeyer G,
    6. Kewitz H,
    7. Roots I
    (1990) Pharmacokinetic interaction between cyclosporin and diltiazem. Eur J Clin Pharmacol 38:237–242.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Buters JTM,
    2. Schiller CD,
    3. Chou RC
    (1993) A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Biochem Pharmacol 46:1577–1584.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Castle PJ,
    2. Merdink JL,
    3. Okita JR,
    4. Wrighton SA,
    5. Okita RT
    (1995) Human liver lauric acid hydroxylase activities. Drug Metab Disp 23:1037–1043.
    OpenUrlAbstract
  10. ↵
    1. Chiba M,
    2. Nishime JA,
    3. Linn JH
    (1995) Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J Pharmacol Exp Ther 275:1527–1534.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Crespi CL,
    2. Penman BW,
    3. Steimel DT,
    4. Smith T,
    5. Yang CS,
    6. Sutter TR
    (1997) Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: Substrate specificity with model substrates and promutagens. Mutagen 12:83–89.
  12. ↵
    1. Ekins S,
    2. Bravi G,
    3. Ring BJ,
    4. Gillespie TA,
    5. Gillespie JS,
    6. Vandenbranden M,
    7. Wrighton SA,
    8. Wikel JH
    (1999) Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. J Pharmacol Exp Ther 288:21–29.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Franklin MR
    (1977) Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes. Pharmacol Ther 2:227–245.
    OpenUrl
  14. ↵
    1. Franklin MR
    (1991) Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods Enzymol 206:559–573.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Gorski JC,
    2. Jones DR,
    3. Haehner-Daniels BD,
    4. Hamman MA,
    5. O’Mara EM, Jr,
    6. Hall SD
    (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133–143.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Gorski JC,
    2. Jones DR,
    3. Wrighton SA,
    4. Hall SD
    (1994a) Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 48:173–182.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Gorski JC,
    2. Hall SD,
    3. Jones DR,
    4. VandenBranden M,
    5. Wrighton SA
    (1994b) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643–1653.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Guengerich FP
    (1990) Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 3:363–371.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Hall SD,
    2. Hamman MA,
    3. Rettie AE,
    4. Wienkers LC,
    5. Trager WF,
    6. VandenBranden M,
    7. Wrighton SA
    (1994) Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Disp 22:975–978.
    OpenUrlPubMed
  20. ↵
    1. Höglund P,
    2. Nilsson L-G
    (1989a) Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers. Ther Drug Monit 11:543–550.
    OpenUrlPubMed
  21. ↵
    1. Höglund P,
    2. Nilsson L-G
    (1989b) Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers. Ther Drug Monit 11:551–557.
    OpenUrlPubMed
  22. ↵
    1. Höglund P,
    2. Nilsson L-G
    (1989c) Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers. Ther Drug Monit 11:558–566.
    OpenUrlPubMed
  23. ↵
    1. Jones DR,
    2. Gorski JC,
    3. Hamman MA,
    4. Hall SD
    (1996) Quantification of dextromethorphan and metabolites: A dual phenotypic marker for cytochrome P450 3A4/5 and 2D6 activity. J Chrom B 678:105–111.
    OpenUrl
  24. ↵
    1. Koudriakova T,
    2. Iatsimirskaia E,
    3. Utkin I,
    4. Gangl E,
    5. Vouros P,
    6. Storozhuk E,
    7. Orza D,
    8. Marinina J,
    9. Gerber N
    (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552–561.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Laganière S,
    2. Davies RF,
    3. Carignan G,
    4. Foris K,
    5. Goernert L,
    6. Carrier K,
    7. Pereira C,
    8. McGilveray I
    (1996) Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine. Clin Pharmacol Ther 60:257–264.
    OpenUrl
  26. ↵
    1. Leibbrandt DM,
    2. Day RO
    (1992) Cyclosporin and calcium channel blockers: An exploitable drug interaction? Med J Aust 157:296–297.
    OpenUrlPubMed
  27. ↵
    1. Miles JS,
    2. McLaren AW,
    3. Forrester LM,
    4. Glancey MJ,
    5. Lang MA,
    6. Wolf CR
    (1990) Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 267:365–371.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Miners JO,
    2. Birkett DJ
    (1996a) The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol 27:245–249.
    OpenUrlPubMed
  29. ↵
    1. Miners JO,
    2. Birkett DJ
    (1996b) Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Meth Enz 272:139–145.
    OpenUrl
  30. ↵
    1. Montamat SC,
    2. Abernethy DR
    (1987) N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. Br J Clin Pharmacol 24:185–189.
    OpenUrlPubMed
  31. ↵
    1. Murray M,
    2. Butler AM
    (1996) Enhanced inhibition of microsomal cytochrome P450 3A2 in rat liver during diltiazem biotransformation. J Pharmacol Exp Ther 279:1447–1452.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Newton DJ,
    2. Wang RW,
    3. Lu AYH
    (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Disp 23:154–158.
    OpenUrlAbstract
  33. ↵
    1. Omura T,
    2. Sato R
    (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2379–2385.
    OpenUrlFREE Full Text
  34. ↵
    1. Pershing LK,
    2. Franklin MR
    (1982) Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics: A new class of agents. Xeno 12:687–699.
    OpenUrl
  35. ↵
    1. Powell PK,
    2. Wolf I,
    3. Lasker JM
    (1996) Identification of CYP4A11 as the major lauric acid ω-hydroxylase in human liver microsomes. Arch Biochem Biophy 335:219–226.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Rohlf FJ,
    2. Sokal RR
    (1981) Statistical Tables (WH Freeman and Co, New York), 2nd ed, pp 166–168.
  37. ↵
    1. Roos PH,
    2. Golub-Ciosk B,
    3. Kallweit P,
    4. Kauczinski D,
    5. Hanstein WG
    (1993) Formation of ligand and metabolite complexes as a means for selective quantitation of cytochrome P450 isozymes. Biochem Pharmacol 45:2239–2250.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Silverman RB
    (1988) Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology (CRC Press, Boca Raton, FL), I:3–30.
  39. ↵
    1. Sutton D,
    2. Butler AM,
    3. Nadlin L,
    4. Murray M
    (1997) Role of CYP3A4 in human hepatic diltilazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 28:294–300.
    OpenUrl
  40. ↵
    1. Toyosaki N,
    2. Toyo-Oka T,
    3. Natsume T,
    4. Katsuki T-A,
    5. Tateishi T,
    6. Yaginuma T,
    7. Hosoda S
    (1988) Combination therapy with diltiazem and nifedipine in patients with effort angina pectoris. Circulation 77:1370–1375.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Varhe A,
    2. Olkkola KT,
    3. Neuvonen PJ
    (1996) Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther 59:369–375.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Voorman RL,
    2. Maio SM,
    3. Payne NA,
    4. Zhao Z,
    5. Koeplinger KA,
    6. Wang X
    (1998) Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 287:381–388.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Waley SG
    (1985) Kinetics of suicide substrates. Biochem J 227:843–849.
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Wedlund PJ,
    2. Wilkinson GR
    (1996) In vivo and in vitro measurement of CYP2C19 activity. Methods Enzymol 272:105–114.
    OpenUrlPubMed
  45. ↵
    1. Wrighton SA,
    2. Maurel P,
    3. Schuetz EG,
    4. Watkins PB,
    5. Young B,
    6. Guzelian PS
    (1985) Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450. Biochemistry 24:2171–2178.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Wrighton SA,
    2. Stevens JC,
    3. Becker GW,
    4. VandenBranden M
    (1993) Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophy 306:240–245.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Yeung PKF,
    2. Buckley SJ,
    3. Hung OR,
    4. Pollak PT,
    5. Barclay KD,
    6. Feng JDZ,
    7. Farmer PS,
    8. Klassen GA
    (1996) Steady-state plasma concentrations of diltiazem and its metabolites in patients and healthy volunteers. Ther Drug Monit 18:40–45.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Diltiazem Inhibition of Cytochrome P-450 3A Activity Is Due To Metabolite Intermediate Complex Formation

David R. Jones, J. Christopher Gorski, Mitchell A. Hamman, Bradley S. Mayhew, Steven Rider and Stephen D. Hall
Journal of Pharmacology and Experimental Therapeutics September 1, 1999, 290 (3) 1116-1125;
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement